Advertisement

Drugs

, Volume 29, Issue 5, pp 455–473 | Cite as

Prodrugs

Do They Have Advantages in Clinical Practice?
  • V. J. Stella
  • W. N. A. Charman
  • V. H. Naringrekar
Review Article

Summary

Prodrugs are pharmacologically inactive chemical derivatives of a drug molecule that require a transformation within the body in order to release the active drug. They are designed to overcome pharmaceutical and/or pharmacokinetically based problems associated with the parent drug molecule that would otherwise limit the clinical usefulness of the drug.

The scientific rationale, based on clinical, pharmaceutical and chemical experience, for the design of various currently used prodrugs is presented in this review. The examples presented are by no means comprehensive, but are representative of the different ways in which the prodrug approach has been used to enhance the clinical efficacy of various drug molecules.

Keywords

Sulindac Phenacetin Pivampicillin Bacampicillin Mask Taste 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Albert, A.: Chemical aspects of selective toxicity. Nature 182: 421–423 (1958).PubMedCrossRefGoogle Scholar
  2. Albert, A.: in Albert (Ed.) Selective Toxicity, pp. 21–62 (John Wiley, New York 1973).Google Scholar
  3. Alibrandi, A.; Brani, G.; Ercoli, A.; Gardi, R. and Meli, A.: Factors influencing the biological activity of orally administered steroid compounds: Effect of the medium and of esterification. Endocrinology 66: 13–18 (1960).PubMedCrossRefGoogle Scholar
  4. Anderson, J.A.; Davis, W.L. and Wei, C-P.: Site of ocular hydrolysis of a prodrug, dipivefrin, and a comparison of its ocular metabolism with that of the compound epinephrine. Investigative Ophthalmology and Visual Science 19: 817–823 (1980).PubMedGoogle Scholar
  5. Andersgaard, H.; Finholt, P.; Gjermundsen, R. and Hoyland, T.: Rate studies on dissolution and enzymatic hydrolysis of chloramphenicol palmitate. Acta Pharmaceutica Suecica 11: 239–248 (1974).PubMedGoogle Scholar
  6. Ariens, E.J.: Molecular pharmacology, a basis for drug design; in Jucker (Ed.) Progress in Drug Research, Vol. 10, pp. 429–529 (Birkhauser Verlag, Basel 1966).Google Scholar
  7. Ariens, E.J.: Modulation of pharmacokinetics by molecular manipulation; in Ariens (Ed.) Drug Design, Vol. II, pp. 1–127 (Academic Press, New York 1971).Google Scholar
  8. Ariens, E.J. and Simonis, A.M.: Drug action: Target tissue, dose-response relationships and receptors; in Torell et al. (Eds) Pharmacology and Pharmacokinetics, pp. 163–189 (Plenum Press, New York 1974).Google Scholar
  9. Atkinson, A.J. and Davison, R.: Diphenylhydantoin as an anti-arrhythmic drug. Annual Reviews of Medicine 25: 99–113 (1974).CrossRefGoogle Scholar
  10. Bey, P.: «Pro-drugs» activees specifiquement par le recepteurcible: Inhibition enzymatic du type kcal. Sciences et Techniques Pharmaceutiques 7: 171–176 (1978).Google Scholar
  11. Bodor, N.: Novel approaches for the design of membrane transport properties of drugs; in Roche (Ed.) Design of Biopharmaceutical Properties through Prodrugs and Analogs, pp. 98–135 (American Pharmaceutical Association, Washington, DC 1977).Google Scholar
  12. Bodor, N.: Novel approaches in prodrug design; in Bundgaard et al. Optimization of Drug Delivery, pp. 156–177 (Munksgaard, Copenhagen 1982).Google Scholar
  13. Bodor, N. and Brewster, M.E.: Improved delivery through biological membranes XV — Sustained brain delivery of berberine. European Journal of Medicinal Chemistry 18: 235–240 (1983).Google Scholar
  14. Bodor, N.; Shek, E. and Higuchi, T.: Delivery of a quaternary pyridinium salt across the blood-brain barrier by its dihydropyridine derivative. Science 190: 155–156 (1975).PubMedCrossRefGoogle Scholar
  15. Bodor, N.; Shek, E. and Higuchi, T.: Improved delivery through biological membranes. 1. Synthesis and properties of 1-methyl-1, 6-dihydropyridine, a pro-drug of N-methylpyridinium-2-carbaldoxime chloride. Journal of Medicinal Chemistry 19: 102–107 (1976).PubMedCrossRefGoogle Scholar
  16. Bolme, P.; Dahlstrom, B.; Diding, N.A.; Flink, O. and Paalzo, L.: Ampicillin: Comparison of bioavailability and pharmacokinetics after oral and intravenous administration of three brands. European Journal of Clinical Pharmacology 10: 237–243 (1976).CrossRefGoogle Scholar
  17. Bundgaard, H.: Spectrophotometric determination of ampicillin sodium in the presence of its degradation and polymerization products. Journal of Pharmacy and Pharmacology 26: 385–392 (1974).PubMedCrossRefGoogle Scholar
  18. Bundgaard, H.: Novel bioreversible derivatives of amides, ureides, amines and other chemical entities not readily derivatizable; in Bundgaard et al. (Eds.) Optimization of Drug Delivery, pp. 178–198 (Munksgaard, Copenhagen 1982).Google Scholar
  19. Bundgaard, H.; Hansen, A.B. and Kofod, H. (Eds.): Optimization of Drug Delivery. Alfred Benzon Symposium 17 (Munksgaard, Copenhagen 1982).Google Scholar
  20. Celmer, C.D.: Canadian Patent 779,315 (Feb 27, 1968).Google Scholar
  21. Clark, R.K. and Varner, E.L.: New esters of erythromycin. Antibiotics and Chemotherapy 7: 487–489 (1957).Google Scholar
  22. Davies, G.E. and Driver, G.W.: The antituberculous activity of ethylthiolesters with particular reference to diethyldithiol isophthalate. British Journal of Pharmacology 12: 434–437 (1957).Google Scholar
  23. Davies, G.E.; Driver, G.W.; Hoggarth, E.; Martin, A.R.; Paige, M.F.C.; Rose, F.L. and Wilson, B.R.: Studies in the chemotherapy of tuberculosis: Ethyl mercaptan and related compounds. British Journal of Pharmacology 11: 351–356 (1956).Google Scholar
  24. DeHaan, R.M.; Metzler, C.M.; Schellenberg, D. and Van-Denbosch, W.D.: Pharmacokinetic studies of clindamycin phosphate. Journal of Clinical Pharmacology 13: 190–209 (1973).PubMedGoogle Scholar
  25. Digenis, G.A. and Swintosky, J.V.: Drug latentiation; in Gillette and Mitchell (Eds) Handbook of Experimental Pharmacology 28 (Part 3), pp. 86–112 (Springer, Berlin, Heidelberg, New York 1975).Google Scholar
  26. Dobrinska, M.R.; Furst, D.E.; Speigel, T.; Vincek, W.C.; Tompkins, R.; Duggan, D.E.; Davies, R.O. and Paulus, H.E.: Biliary secretion of sulindac and metabolites in man. Biopharmaceutics and Drug Disposition 4: 347–358 (1983).CrossRefGoogle Scholar
  27. Duggan, D.E.: Sulindac: Therapeutic implications of the prodrug/pharmacophore equilibrium. Drug Metabolism Reviews 12: 325–337 (1981).PubMedCrossRefGoogle Scholar
  28. Duggan, D.E.; Hare, L.E.; Ditzler, C.A.; Lei, B.W. and Kwan, K.C.: The disposition of sulindac. Clinical Pharmacology and Therapeutics 21: 326–335 (1977).PubMedGoogle Scholar
  29. Duggan, D.E.; Hooke, K.F. and Hwang, S.S.: Kinetics of the tissue distributions of sulindac and metabolites. Drug Metabolism and Disposition 8: 241–246 (1980).PubMedGoogle Scholar
  30. Edmondson, H.T.: Parenteral and oral clindamycin therapy in surgical infections — preliminary report. Annals of Surgery 178: 637–642 (1973).PubMedCrossRefGoogle Scholar
  31. Ehrnebo, M.; Nilsson, S. and Boreus, L.O.: Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man. Journal of Pharmacokinetics and Biopharmaceutics 7: 429–451 (1979).PubMedGoogle Scholar
  32. Glazko, A.J.; Carnes, H.E.; Kazenko, A.; Wolf, L.M. and Reutner, T.P.: Succinic acid esters of chloramphenicol. Antibiotics Annual: 792–802 (1957–58).Google Scholar
  33. Glazko, A.J.; Edgerton, W.H.; Dill, W.A. and Lenz, W.R.: Chloromycetin palmitate: A synthetic ester of Chloromycetin. Antibiotics and Chemotherapy 2: 234–242 (1952).Google Scholar
  34. Gray, J.E.; Weaver, R.N.; Moran, J. and Feenstra, E.S.: The parenteral toxicity of clindamycin-2-phosphate in laboratory animals. Toxicology and Applied Pharmacology 27: 308–321 (1974).PubMedCrossRefGoogle Scholar
  35. Gray, L.H.; Conger, A.D.; Ebert, M.; Hornsey, S. and Scott, O.C.A.: The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. British Journal of Radiology 86: 638–648 (1953).CrossRefGoogle Scholar
  36. Gregoriadis, G.: Targetting of drugs. Nature 265: 407–411 (1977).PubMedCrossRefGoogle Scholar
  37. Gregoriadis, G. (Ed.): Drug Carriers in Biology and Medicine (Academic Press, New York 1979).Google Scholar
  38. Gruber, J.C.M.; Stephens, V.C. and Terrill, P.M.: Propoxyphene napsylate: Chemistry and experimental design. Toxicology and Applied Pharmacology 19: 423–426 (1971).PubMedCrossRefGoogle Scholar
  39. Harper, N.J.: Drug latentiation. Journal of Medicinal and Pharmaceutical Chemistry 1: 467–500 (1959).PubMedCrossRefGoogle Scholar
  40. Harper, N.J.: Drug latentiation. Progress in Drug Research 4: 221–294 (1962).Google Scholar
  41. Higuchi, T. and Stella, V. (Eds.): Pro-drugs as Novel Drug Delivery Systems (American Chemical Society, Washington, DC 1975).Google Scholar
  42. Ho, N.F.H.; Park, J.Y.; Morozowich, W. and Higuchi, W.I.: Physical model approach to the design of drugs with improved intestinal absorption; in Roche (Ed.) Design of Biopharmaceutical Properties through Prodrugs and Analogs, pp. 136–227 (American Pharmaceutical Association, Washington, DC 1977).Google Scholar
  43. James, K.C.; Nichols, P.J. and Roberts, M.: Biological half-lives of [4–14C] testosterone and some of its esters after injection into the rat. Journal of Pharmacy and Pharmacology 21: 24–27 (1969).PubMedCrossRefGoogle Scholar
  44. Jorgensen, A.: Pharmacokinetic studies on flupenthixol decanoate, a depot neuroleptic of the thioxanthene group. Drug Metabolism Reviews 8: 235–250 (1978).PubMedCrossRefGoogle Scholar
  45. Juliano, R.L. (Ed.): Drug Delivery Systems: Characteristics and Biomedical Applications (Oxford University Press, New York 1980).Google Scholar
  46. Krish, K.: Carboxylic ester hydrolases; in Boyer (Ed.) The Enzymes, Vol. V, pp. 43–69 (Academic Press, New York 1971).Google Scholar
  47. Kupchan, S.M.; Casy, A.F. and Swintosky, J.V.: Drug latentiation: Synthesis and preliminary evaluation of testosterone derivatives. Journal of Pharmaceutical Sciences 54: 514–524 (1965).PubMedCrossRefGoogle Scholar
  48. Kyncl, J.J.; Minard, R.N. and Jones, P.H.: L-γ-glutamyl dopamine, an oral dopamine prodrug with renal selectivity; in Impsand and Schwartz (Eds.) Peripheral Dopaminergic Receptors, pp. 369–380 (Pergamon Press, New York 1979).Google Scholar
  49. Loo, J.C.K.; Foltz, E.L.; Wallick, H. and Kwan, K.C.: Pharmacokinetics of pivampicillin and ampicillin in man. Clinical Pharmacology and Therapeutics 16: 35–43 (1974).PubMedGoogle Scholar
  50. Magni, L.; Sjoberg, G.; Sjovall, J. and Wessman, J.: Clinical pharmacological studies with bacampicillin; in Williams and Geddes (Eds.) Chemotherapy, Vol. 5, pp. 109–114 (Plenum, New York 1976).Google Scholar
  51. Mandell, A.I.; Stentz, F. and Kitabchi, A.B.: Dipivalyl epinephrine: A new prodrug in the treatment of glaucoma. Ophthalmology 85: 268–275 (1978).PubMedGoogle Scholar
  52. McClure, D.A.: The effect of a pro-drug of epinephrine (dipivalyl epinephrine) in glaucoma — general pharmacology, toxicology and clinical experience; in Higuchi and Stella (Eds.) Pro-drugs as Novel Drug Delivery Systems, pp. 224–235 (American Chemical Symposium Series, Washington, DC 1975).CrossRefGoogle Scholar
  53. McEvoy (Ed.): American Hospital Formulary Service, Vol. 8, p. 24 (American Society of Hospital Pharmacists, Washington, DC 1974).Google Scholar
  54. Melby, J.C. and St Cyr, M.: Comparative studies on absorption and metabolic disposal of water-soluble corticosteroid esters. Metabolism 10: 75–82 (1961).PubMedGoogle Scholar
  55. Morozowich, W.; Sinkula, A.A.; Karnes, H.A.; MacKellar, F.A.; Lewis, C.; Stern, K.F. and Rowe, E.L.: Synthesis and bioactivity of lincomycin-2-phosphate. Journal of Pharmaceutical Sciences 58: 1485–1489 (1969).PubMedCrossRefGoogle Scholar
  56. Morozowich, W.; Sinkula, A.A.; MacKellar, F.A. and Lewis, C.J.: Synthesis and bioactivity of lincomycin-2-monoesters. Journal of Pharmaceutical Sciences 62: 1102–1105 (1973).PubMedCrossRefGoogle Scholar
  57. Murphy, H.W.: Esters of erythromycin. Antibiotics Annual: 500–521 (1953–54).Google Scholar
  58. Nahata, M.C. and Powell, D.A.: Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate. Clinical Pharmacology and Therapeutics 30: 368–372 (1981).PubMedCrossRefGoogle Scholar
  59. Notari, R.E.: Prodrug design. Pharmacology and Therapeutics 14: 25–53 (1981).PubMedCrossRefGoogle Scholar
  60. Pang, K.S. and Gillette, J.R.: Kinetics of metabolite formation and elimination in the perfused rat liver preparation: Differences between the elimination of preformed acetaminophen and acetaminophen formed from phenacetin. Journal of Pharmacology and Experimental Therapeutics 207: 178–194 (1978).PubMedGoogle Scholar
  61. Redwood, D.: Conservative treatment of chronic heart block. British Medical Journal 1: 26–29 (1969).PubMedCrossRefGoogle Scholar
  62. Repta, A.J.; Hageman, M.J. and Patel, J.P.: Enol esters as potential prodrugs. IV. Enhanced delivery of the quaternary species coralyne to rat brain using 6′-acetylpapaverin and its enol esters as prodrugs. International Journal of Pharmaceutics 10: 239–248 (1982).CrossRefGoogle Scholar
  63. Roche, E.B. (Ed.): Design of Biopharmaceutical Properties through Prodrugs and Analogs (American Pharmaceutical Association, Washington, DC 1977a).Google Scholar
  64. Roche, E.B.: Structural aspects of selective distribution; in Roche (Ed.) Design of Biopharmaceutical Properties through Prodrugs and Analogs, pp. 27–46 (American Pharmaceutical Association, Washington, DC 1977b).Google Scholar
  65. Saari, W.S.; Freeman, M.B.; Hartman, R.D.; King, S.W.; Raab, A.W.; Randall, W.C.; Engelhardt, E.L.; Hirschmann, R.; Rosegay, A.; Ludden, C.T. and Scriabine, A.: Synthesis and antihypertensive activity of some ester progenitors of methyldopa. Journal of Medicinal Chemistry 21: 746–753 (1978).PubMedCrossRefGoogle Scholar
  66. Schwartz, M.A. and Hayton, W.I.: Relative stability of hetacillin and ampicillin in solution. Journal of Pharmaceutical Sciences 61: 906–909 (1972).PubMedCrossRefGoogle Scholar
  67. Shek, E.; Higuchi, T. and Bodor, N.: Improved delivery through biological membranes. 2. Distribution, excretion and metabolism of N-methyl-1, 6-dihydropyridine-2-carbaldoxime hydrochloride, a prodrug of N-methylpyridinium-2-carbaldoxime chloride. J. Med. Chem. 19: 108–112 (1976a).PubMedCrossRefGoogle Scholar
  68. Shek, E.; Higuchi, T. and Bodor, N.: Improved delivery through biological membranes. 3. Delivery of N-methylpyridinium-2-carbaldoxime chloride through the blood brain barrier in its dihydropyridine pro-drug form. Journal of Medicinal Chemistry 19: 113–117 (1976b).PubMedCrossRefGoogle Scholar
  69. Shen, T-S. and Winter, C.A.: Chemical and biological studies on indomethacin, sulindac and their analogs; in Harper and Simmonds (Eds) Advances in Drug Research, Vol. 12, pp. 89–246 (Academic Press, New York 1977).Google Scholar
  70. Simon, C.; Malerczyk, V. and Klans, M.: Absorption of bacampicillin and ampicillin and penetration into body fluids in healthy volunteers. Scandinavian Journal of Infectious Diseases 14 (Suppl.): 228–235 (1978).PubMedGoogle Scholar
  71. Sinkula, A.: Prodrug approach in drug design. Annual Reports in Medicinal Chemistry 10: 306–316 (1975).CrossRefGoogle Scholar
  72. Sinkula, A.A.: Perspective on prodrugs and analogs in drug design; in Roche (Ed.) Design of Biopharmaceutical Properties through Prodrugs and Analogs, pp. 1–17 (American Pharmaceutical Association, Washington, DC 1977).Google Scholar
  73. Sinkula, A.A.: Methods to achieve sustained drug delivery — The chemical approach; in Robinson (Ed.) Sustained and Controlled Release Drug Delivery Systems, pp. 411–555 (Marcel Dekker, New York 1978).Google Scholar
  74. Sinkula, A.A. and Lewis, C.: Chemical modifications of lincomycin: Synthesis and bioactivity of selected 2,7-dialkylcarbonate esters. Journal of Pharmaceutical Sciences 62: 1757–1760 (1973).PubMedCrossRefGoogle Scholar
  75. Sinkula, A.; Morozowich, W. and Rowe, E.L.: Chemical modification of clindamycin: Synthesis and evaluation of selected esters. Journal of Pharmaceutical Sciences 62: 1106–1111 (1973).PubMedCrossRefGoogle Scholar
  76. Sinkula, A. and Yalkowsky, S.: Rationale for design of biologically reversible drug derivatives: Prodrugs. Journal of Pharmaceutical Sciences 64: 181–210 (1975).PubMedCrossRefGoogle Scholar
  77. Sjovall, J.; Magni, L. and Bergan, T.: Pharmacokinetics of bacampicillin compared with those of ampicillin, pivampicillin and amoxicillin. Antimicrobial Agents and Chemotherapy 13: 90–96 (1978).PubMedCrossRefGoogle Scholar
  78. Stella, V.J.: Chemical modification of drugs to overcome pharmaceutical problems. Australian Journal of Pharmaceutical Sciences NS2: 57–63 (1973).Google Scholar
  79. Stella, V.: Prodrugs: An overview and definition; in Higuchi and Stella (Eds.) Pro-drugs as Novel Drug Delivery Systems, pp. 1–115 (American Chemical Society, Washington, DC 1975).CrossRefGoogle Scholar
  80. Stella, V.J.: Drug substances in particular prodrugs: Problems and methods of approach; in Polderman (Ed.) Formulation and Preparation of Dosage Forms, pp. 91–111 (Elsevier/North-Holland, Amsterdam 1977).Google Scholar
  81. Stella, V.J. and Himmelstein, K.J.: Prodrugs and site specific delivery. Journal of Medicinal Chemistry 23: 1275–1282 (1980).PubMedCrossRefGoogle Scholar
  82. Stella, V.J. and Himmelstein, K.J.: Critique of prodrugs and site specific delivery; in Bundgaard et al. (Eds) Optimization of Drug Delivery — Alfred Benzon Symposium 17, pp. 134–155 (Munksgaard, Copenhagen 1982).Google Scholar
  83. Stewart, G.T.: Macromolecular residues contributing to the allergenicity of penicillins and cephalosporins. Antimicrobial Agents and Chemotherapy 7: 543–549 (1967).PubMedGoogle Scholar
  84. Stewart, G.T.: Proteinaceous and polymeric residues in β-lactam antibiotics and bacitracins. Antimicrobial Agents and Chemotherapy 8: 128–135 (1968).PubMedGoogle Scholar
  85. Tanaka, T.; Kobayashi, H.; Okumura, K.; Muranishi, S. and Sezaki, H.: Intramuscular absorption of drugs from oily solutions in the rat. Chemical and Pharmaceutical Bulletin 22: 1275–1284 (1974).CrossRefGoogle Scholar
  86. Theeuwes, F.: Elementary osmotic pumps. Journal of Pharmaceutical Sciences 64: 1987–1991 (1975).PubMedCrossRefGoogle Scholar
  87. Vane, J.R.: in Robinson and Vane (Eds) Prostaglandin Synthetase Inhibitors: Their Effects on Physiological Functions and Pathological States, p. 155 (Raven Press, New York 1974).Google Scholar
  88. Varia, S.A.; Schuller, S.; Sloan, K.B. and Stella, V.J.: Phenytoin prodrugs. III: Water soluble prodrugs for oral and/or parenteral use. Journal of Pharmaceutical Sciences 73: 1068–1073 (1984a).PubMedCrossRefGoogle Scholar
  89. Varia, S.A.; Schuller, S. and Stella, V.J.: Phenytoin prodrugs. IV: Chemical stability of various 3-(hydroxymethyl)-phenytoin esters. Journal of Pharmaceutical Sciences 73: 1074–1079 (1984b).PubMedCrossRefGoogle Scholar
  90. Varia, S.A. and Stella, V.J.: Phenytoin prodrugs. V: In vivo evaluation of some water soluble phenytoin prodrugs in dogs. Journal of Pharmaceutical Sciences 73: 1080–1086 (1984c).PubMedCrossRefGoogle Scholar
  91. Varia, S.A. and Stella, V.J.: Phenytoin prodrugs. VI: In vivo evaluation of a phosphate ester prodrug of phenytoin after parenteral administration to rats. Journal of Pharmaceutical Sciences 73: 1087–1090 (1984d).PubMedCrossRefGoogle Scholar
  92. Vickers, S.; Duncan, C.A.; White, S.D.; Breault, G.O.; Royds, K.B.; deSchepper, P.J. and Tempero, K.F.: Evaluation of succinoimidoethyl and pivaloyloxyethyl esters as progenitors of methyldopa in man, rhesus monkey, dog and rat. Drug Metabolism and Disposition 6: 640–646 (1978).PubMedGoogle Scholar
  93. Villeneuve, A.; Pires, A.; Jus, A.; Lachance, R. and Drolet, A.: A long-term pilot study of pipothiazine palmitate in chronic schizophrenia. Current Therapeutic Research — Clinical and Experimental 14: 696–706 (1972).Google Scholar
  94. Wilk, S.; Mizoguchi, H. and Orlowski, M.: γ-Glutamyl dopa: A kidney specific dopamine precursor. Journal of Pharmacology and Experimental Therapeutics 206: 227–232 (1978).PubMedGoogle Scholar
  95. Yale, H.L.: Esters of 4[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazine ethanol and related compounds as long-acting antipsychotic agents. Synthesis of the 1-adamantsoate, the first crystalline base 4. Journal of Medicinal Chemistry 20: 302–304 (1977).PubMedCrossRefGoogle Scholar
  96. Yale, H.L.: The long acting neuroleptics: A retrospective appraisal. Drug Metabolism Reviews 8: 251–264 (1978).PubMedCrossRefGoogle Scholar
  97. Yalkowsky, S.H. and Morozowich, W.: A physical chemical basis for the design of orally active prodrugs; in Ariens (Ed.) Drug Design, Vol. IX, pp. 121–185 (Academic Press, New York 1980).Google Scholar

Copyright information

© ADIS Press Limited 1985

Authors and Affiliations

  • V. J. Stella
    • 1
  • W. N. A. Charman
    • 1
  • V. H. Naringrekar
    • 1
  1. 1.Department of Pharmaceutical ChemistryUniversity of Kansas, School of PharmacyLawrenceUSA

Personalised recommendations